Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 1
Submit an article Journal homepage
48
Views
15
CrossRef citations to date
0
Altmetric
Miscellaneous

PDE4 inhibitors 2001. Patent and literature activity 2000 - September 2001

Peter Norman 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK
Pages 93-112 | Published online: 25 Feb 2005

Bibliography

  • NORMAN P: PDE4 Inhibitors 1999. Expert Opin. Ther. Patents. (1999) 9:1101–1118.
  • ••Previous review in this series.
  • NORMAN P: PDE4 Inhibitors. Expert Opin. Ther. Patents (2000) 10:1415–1427.
  • ••Previous review in this series.
  • MARTIN T: PDE4 inhibitors - a review of the recent patent literature. Curr. Opin. Investig. Drugs (2001) 4:312–338.
  • DYKE HJ, MONTANA JG: The Therapeutic Potential of PDE4 Inhibitors. Expert Opin. Investig. Drugs (1999) 8:1301–1325.
  • ••Useful review that considers various therapeutic opportunities and current developments.
  • DOHERTY AM: Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr Opin. Chem. Biol. (1999) 3:466–473
  • •Another medicinal chemistry orientated review from a different perspective
  • DYKE HJ, MONTANA JG: Update on the therapeuticl potential of PDE4 inhibitors. Expert Opin. Investig. Drugs (2002) 11(1):1–13.
  • HUANG Z, DUCHARME Y, MACDONALD D, ROBICHAUD A: The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. (2001) 5:432–438.
  • HAY DWP: Chronic obstructive pulmonary disease: emerging therapies. Curr Opin. Chem. Biol. (2000) 4:412–419.
  • COOMBES J: Merrill Lynch Global Pharmaceutical Investor Conference. London, UK September 25 (2001)
  • COMPTON C, EDELSON JD, CEDAR E et al.: Cilomilast (Ariflo) 15 mg bid safety in a six month clinical trial program. Am. Respir. Grit. Care Med. (2001) 163: A909.
  • •Abstract summarising the Phase III data.
  • ZUSSMAN BD, DAVIE CC, KELLY J et al.: Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy (2001) 21(6):653–660.
  • ZUSSMAN BD, BENINCOSA LJ, WEBBER DM et al: An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. j Clin. Pharmacol. (2001) 41(9):950–958.
  • COMPTON CH, GUBB J, NIEMAN R et al.: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet (2001) 358(9278):265–270.
  • ••The most significant clinical datapublished yet on a PDE4 inhibitor.
  • GIEMBYCZ MA: Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2001) 10 (7):1361–1379.
  • •Comprehensive, up to date review.
  • RENNARD SI, EDELSON JD, ROBINSON CB et al: Cilomilast reduces the percentage of sputum neutrophils in patients with chronic obstructive pulmonary disease (COPD) Chest (2001) 120: Suppl. 45S
  • DUPLANTIER AJ, BIGGERS MS, CHAMBERS RJ et al: Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase Type IV versus PFIlrolipram binding activity and their relationship to emetic behavior in the ferret. Med. Chem. (1996) 39:120–125.
  • CHRISTENSEN SB, GUIDER A, FORSTER CJ et al: 1,4-cyclohexane-carboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. j Med. Chem. (1998) 41:821–835.
  • TORPHY TJ: Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am. J. Respir Grit. Care Med. (1998) 157: 351–370.
  • ••Still the outstanding review on PDE4inhibition.
  • UNDERWOOD DC, BOCHNOWICZ S, OSBORN RR. et al: Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. j Pharmacol Exp. Ther (1998) 287:988–995.
  • ALTANA AG: (2000) Annual Report March 2001
  • SCHMIDT BM, KUSMA M, FEURING M et al: The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. j Allergy Chit. hinnurtol. (2001) 108(4):530–536.
  • HATZELMANN A, SCHUDT C: Anti-inflammatory and immunomodulatory potential of the novel pde4 inhibitor roflumilast in vitro. j Phannacol Exp. Ther. (2001) 297(1):267–279.
  • •In vitro characterisation.
  • BUNDSCHUH DS, ELTZE M, BARSIG J et al.: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. j Pharmacol Exp. Ther (2001) 297(1):280–290.
  • ••Comprehensive in vivo characterisationand comparison with standard PDE4 inhibitors.
  • ZECH K, DAVID M, SEIBERLING M et al.: High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor ERS 2001:A256.
  • DAVID M, BETHKE T, HARTMANN A et al.: Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor ERS 2001:A377.
  • RADTKE HW: Development of master allergic mediators SMI Conference - Asthma: New Drug Targets & Irinnovative Therapeutics (2001).
  • W TIMMER, V LECLERC, G BIRRAUX et al.: Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks. Am. I Respir Grit. Care Med. (2000) 161:A505.
  • H NELL, S LEICHTL, F RATHGEB et al Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose. Am. I Respir Grit. Care Med. (2000) 161:A200.
  • ALTANA AG: Company presentation, March 2001.
  • BAYER AG: Bayer's pharmaceutical research strategy pays off: more than 40 substances in the pipeline - development of asthma drug halted at Phase II - submission of registration dossier for vardenafll scheduled for fall 2001. News Release (2001) June 12.
  • STURTON RG, BUTT NM, PALFAI SP et al: Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004. Am. I Respir. Crit. Care Med. (2000) 161:A200.
  • FITZGERALD MF, BRIGGS BA, THOMPSON AM et al:The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor, Bay 19-8004, in guinea-pig antigen challenge and ferret emesis models Am. I Respir Grit. Care Med. (2000) 161:A201.
  • FITCH N, FREEMAN MS, STURTON RG et al.: The effect of an oral phosphodiesterase (PDE) 4 inhibitor Bay 19–8004 in primate asthma models. Am. Respir Grit. Care Med (2000) 161:A201. Indicative of the high oral potency of this novel PDE4 inhibitor.
  • Schering AG: pipeline, 22 June 2001.
  • DINTER H, TSE J, HALKS-MILLER M et al.: The Type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. Neuroimmuriol. 2000 Aug 1;108(1-2):136–146.
  • HUNT HJ, MONTANA JG, COOPER N et al.: The profile of SCH351591, a novel phosphodiesterase 4 inhibitor. 1 1 th RSC-SCI Medicinal Chemistry Symposium. Cambridge, UK September 2001.
  • AOKI M, KOBAYASHI M, ISHIKAWA J et al.: A novel phosphodiesterase Type 4 inhibitor, YM976 (4- (3-chloropheny1)-1,7-diethylpyrido [2, 3- d] pyrimidin- 2 (1H) -one), with little emetogenic activity. j Pharmacol Exp. Ther. 2000 Oct 295(1):255–260.
  • AOKI M, FUKUNAGA M, SUGIMOTO T etal.: Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase Type 4 inhibitor. Pharmacol Exp. Ther (2001) 298(3):1142–1149.
  • AOKI M, FUKUNAGA M, KITAGAWA M et al: Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets. j Pharmacol Exp. Ther. (2000) 295(3):1149–1455.
  • AOKI M, YAMAMOTO S, KOBAYASHI M et al: Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. Pharmacol Exp. Ther (2001) 297(1):165–173.
  • PRUNIAUX MP, MOTTIN G, PLANQUOIS JM, BERTRAND C: The selective phosphodiesterase 4 inhibitor CI-1044 (PD-189659) inhibits LPS-induced neutrophil recruitment and TNF-alpha release in rat airways. Am. I Respir: Crit. Care Med (2001) 163:A991.
  • OUAGUED M, MARTIN-CHOULY C, LEPORTIER C et al; The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFa production in whole blood of COPD patients ERS September 2001, Berlin P333, Germany (2001).
  • YAMANA K, SUZUKI N, OTAN T: NIK-616, a new type of selective phosphodiesteraseIV (PDE IV) inhibitor with reduced emetic activity, ERS September 2001, Berlin P335, Germany (2001).
  • KARPINSKI JM, BARNETTE MJ, BOCHNOWICZ S et al: Comparison of the PDE4 activities of Ariflo (SB 207499) with related 4-acetylenic substituted cyclohexyl alcohols and amines 221k ACS San Diego, USA (2001). MEDI 251.
  • VAN DER MEY M, HATZELMANN A, VAN DER LAAN IJ et al.: Novel selective PDE4 inhibitors. 1. synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-Dimethoxyphenyfl -2H-phthalazin-1-ones and analogues. I Med. Chem. 2001 44 (17) 2511–2522.
  • VAN DER MEY M, HATZELMANN A, VAN KLINK GPM et al.: Novel selective PDE4 inhibitors. 2. synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones. Med. Chem. 2001 44 (17) 2523–2535.
  • BURNOUF C, AUCLAIR E, AVENEL N et al: Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-pheny1-3,4,6,7-tetrahydro [1, 4] diazepino [6, 7,1-hi] indoles: discovery of potent, selective phosphodiesterase Type 4 inhibitors. Med. Chem. (2000) 43(26):4850–4867.
  • PASCAL Y, ANDRIANJARA CR, AUCLAIR E et at Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3, 4, 6,7-tetrahydro- [1,4] diazepino [6,7,1 - hi] indoles: novel PDE4 inhibitors. Bioorg. Med. Chem. Lett. (2000) 10(1):35–38
  • FRENETTE R. BLOUIN M, BRIDEAU C et al.: Substituted 4- (2,2-diphenylethyfl - pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters 221k ACS San Diego, USA (2001). MEDI 247
  • GIRARD Y, BLOUIN M, BRIDEAU etai; Phenyl substituted analogs of CDP-840 as phosphodiesterase-4 inhibitors with improved potency, oral activity, and metabolic stability. 80 Canadian Society for Chemistry Conference. Montreal, Canada (2001).
  • BUCKLEY G, COOPER N, DYKE HJ et al.: 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma Bioorg. Med Chem. Lett. (2000) 10(18):2137–2140.
  • NAPOLETANO M, NORCINI G, PELLACINI F et al.: The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I. Bioorg. Med. Chem. Lett. (2000)10:2235–2239
  • NAPOLETANO M, NORCINI G, PELLACINI F et al.: Phthalazine PDE4 inhibitors. II: The synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives. Bioorg. Med Chem. Lett. (2001) 11:33–37.
  • NAPOLETANO M, NORCINI G, PELLACINI F et al.: Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor. Bioorg. Med. Chem. Lett. (2001) 11. In press.
  • MORAZZONI G, FERLENGA P, ALLIEVI L et al.: Pharmacological characterization of Z1 5370A, a novel selective phosphodiesterase 4 inhibitor. Am. Respir: Grit. Care Med. (2001) 163:A431.
  • NAPOLETANO M, NORCINI G, PELLACINI F et at. Phthalazine PDE4 inhibitors.Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor. Bioorg.Med.Chem.Lett. (2002) 12:5–8
  • KELLER TH, BRAY-FRENCH K, DEMNITZ FW et al: Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes. Chem. Pharm. Bull (Tokyo). (2001) 49(8):1009–1017.
  • HERSPERGER R, BRAY-FRENCH K, MAZZONI L et al: Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase Type 4D inhibitors. J Med. Chem. (2000) 43(4):675–682.
  • •Interesting paper describing highly selective PDE4D inhibitors.
  • HERSPERGER R, DAWSON J, MUELLER T: Synthesis of 4-(8-benzo-[1, 2,51oxadiazol 5 yl [1,71naphthyridin-6-y1)-benzoic acid: a potent and selective phosphodiesterase Type 4D inhibitor. Bioorg. Med. Chem. Lett. (2001)11. In press.
  • CHARPIOT B, BITSCH F, BUCHHEIT K-H et al: Disease activated drugs: a new concept for the treatment of asthma. Bioorg. Med. Chem. (2001) 9: 7.1793–1805.
  • XU RX, HASSELL AM, VANDERWALL D et al: Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. (2000) 288(5472):1822–1825.
  • RICHTER W, UNCIULEAC L, HERMSDORF T et al: Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis. Cell Signal. (2001) 13(3):159–167.
  • RICHTER W, UNCIULEAC L, HERMSDORF T et al.: Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. Cell Signal. (2001) 13(4):287–297.
  • LALIBERTÉ F, HAN Y, GOVINDARAJAN A et al.: Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry (2000) 39(22):6449–6458.
  • LIU S, LALIBERTÉ 1 BOBECHKO B et al.: Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry (2001) 40 (35) :10179–10186.
  • MACDONALD D, PERRIER H, LIU S et al.: Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8- (3-azidopheny1)-6-[(4-iodo-1H-1-imidazolyfi methyl]quinoline (APIIMQ). j Med. Chem. (2000) 43(22)3820–3823.
  • ROBICHAUD A, SAVOIE C, STAMATIOU PB et al.: PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology (2001) 40(2):262–269.
  • ROBICHAUD A, TATTERSALL FD, CHOUDHURY I, RODGER IW: Emesis induced by inhibitors of Type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology (1999) 38(2):289–297.
  • HOUSLAY MD: PDE4 cAMP-specific phosphodiesterases. Frog. Nucleic Add Res. Md. Biol. (2001) 69:249–315.
  • ••Comprehensive review of the PDE4 filedfrom a biochemical perspective.
  • NORMAN P: Next generation respiratory disease therapeutics, an analysis of key competitor therapeutic pipelines. Decision Resources DR Report (2001). In press.
  • •Providing a detailed assessment of the commercial prospects of the PDE4 inhibitors in late stage development.
  • HANSEN G, JIN SC, UMETSU DT et al.: Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Nati Acad. Sci. USA (2000) 97:6751–6757.

Websites

  • Yamanouchi Pharmaceuticals: www.yamanouchi.com/eghl/fl0105/ E_3.pdf September 2001.
  • GlaxoSmithKline plc: corp.gsk.com/ financial/quarterlyreports.htm October 2001.
  • Altana AG: www.altana.de/download/ ap_conference220801.ppt 22 August 2001.
  • JapanCorpNet www.japancorp.net/ Article.Asp?Art_ID982.
  • Icos Pharmaceuticals: www.icos.com/ research/researchPipeline.html.
  • Inflazyme Pharmaceuticals: www.inflazyme.corn/PDE4_body.htma

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.